Epirubicin (4’-Epi-doxorubicin)

Overview

Epirubicin is a cytotoxic anthracycline chemotherapeutic agent and a semisynthetic stereoisomer of doxorubicin, used in veterinary oncology in dogs and cats. It is utilized for the treatment of various malignancies, with efficacy comparable to doxorubicin but with potentially reduced cardiotoxicity.

Epirubicin is administered intravenously and may be used alone or as part of combination chemotherapy protocols. Due to its potent cytotoxic effects, careful handling, precise dosing, and controlled administration are essential to minimize complications, particularly tissue damage from extravasation.

Mechanism of Action (MOA): Epirubicin exerts its antitumor effects through multiple mechanisms. It binds irreversibly to DNA, inhibiting replication and transcription, and generates cytotoxic free radicals within cells. These actions result in disruption of cellular function and induction of cell death. It also alters cell-membrane function and acts throughout the cell cycle, inhibiting DNA, RNA and protein synthesis, and possesses some immunosuppressant activity.

Indications

Epirubicin is used in dogs and cats as a chemotherapeutic agent for the management of various malignant neoplasms. It may be administered as a single agent or as part of combination chemotherapy protocols depending on tumor type and clinical stage.

• Lymphoma: Used in dogs for lymphoma, with efficacy comparable to doxorubicin.
• Splenic hemangiosarcoma (adjunctive therapy): Used in dogs following splenectomy as part of multimodal treatment.
• Histiocytic sarcoma: Used for canine histiocytic sarcoma, including with lomustine or as a rescue agent, but reported success has been marginal.
• Other sarcomas and carcinomas: Used sporadically in selected other sarcomas and carcinomas.
• Feline injection-site sarcoma: Has been used in cats with injection-site sarcoma; in one study it was given before surgical resection and was associated with tumour- and disease-free survival.

Dosage (Reference)

Dog

In dogs, epirubicin is administered as an intravenous chemotherapeutic agent, typically every 3 weeks as part of oncology protocols. Dosing is based on body surface area (m²), with adjustments in small dogs.

Cat

In cats, epirubicin is used intravenously, mainly in the treatment of injection-site sarcoma and other neoplasms.

Warnings & Precautions

Epirubicin is a potent cytotoxic chemotherapeutic agent that requires careful handling, administration, and patient monitoring to minimize serious complications. Proper technique and patient selection are critical for safe use.

• IV administration only: Must be given strictly intravenously; extravasation can cause severe tissue necrosis, so a well-placed indwelling catheter is essential.
• Administration technique: Administer by slow intravenous injection or infusion through a freely running IV line (preferably 0.9% sodium chloride) over at least 10 minutes. Slower administration (10–20 minutes) may further reduce the risk of hypersensitivity reactions.
• Cardiotoxicity risk: Epirubicin may be less cardiotoxic than doxorubicin, but cumulative dose-dependent cardiomyopathy and congestive heart failure can still occur; use with caution in patients with or predisposed to cardiac disease.
• Hematologic monitoring: Regular monitoring of CBC and platelet counts is essential due to risk of severe bone marrow suppression.
• Myelosuppression precautions: Monitor complete blood counts before each dose. Delay or suspend treatment if clinically significant myelosuppression develops (e.g., neutrophils <2.5 × 10⁹/L or platelets <50 × 10⁹/L). If hematologic toxicity recurs after recovery, consider reducing subsequent doses by 10–25%.
• Gastrointestinal toxicity: Monitor for vomiting, anorexia, or severe GI signs; dose adjustments may be necessary with recurrent toxicity.
• MDR1 mutation (dogs): Dogs carrying an ABCB1 (MDR1) mutation may be at higher risk of toxicity; consider an empiric 25–30% dose reduction with close monitoring.
• Handling safety: Should only be prepared and administered by trained personnel due to its cytotoxic nature.
• Look-alike drug names: Do not confuse EPIrubicin with DOXOrubicin or DAUNOrubicin.
• Occupational hazard (NIOSH): NIOSH classifies epirubicin as a hazardous drug; use appropriate personal protective equipment during preparation and administration.
• Contraindications: Based on human data considered likely applicable to dogs, avoid or carefully weigh risk versus benefit in patients with myelosuppression, severe myocardial insufficiency, cardiomyopathy or heart failure, recent myocardial infarction, severe arrhythmias, or prior maximum cumulative anthracycline exposure; these contraindications are not established in cats.
• Reproductive safety: Teratogenic and embryotoxic and may reduce fertility; verify pregnancy status before dosing intact patients, and use a milk replacer if the dam is nursing (drug is excreted in milk above plasma levels).
• Hepatic / metabolic caution: Use cautiously in patients with hyperuricaemia, hyperuricuria or impaired hepatic function; evaluate hepatic function before treatment and consider a dosage adjustment in hepatic impairment.
• Cardiac monitoring: In dogs with pre-existing cardiac disease, monitor with physical examination and auscultation, ECG and/or echocardiography; cardiac troponin I may serve as a surrogate biomarker. Monitor cardiomyopathy-predisposed breeds (Dobermans, Great Danes, rottweilers, boxers) carefully.
• Exposure & spills: After accidental skin or mucous-membrane contact, wash immediately with soap and copious water; manage spills with sodium hypochlorite containing 1% available chlorine, then dilute further with water.
• Laboratory effect: May increase blood and urine uric-acid concentrations.

Drug Interactions

Clinically relevant interactions with epirubicin are mainly related to increased toxicity, incompatibility, or additive myelosuppressive effects. Careful consideration and monitoring are required when combining with the following drugs.

• Heparin: Physically incompatible; co-administration results in precipitation and should be avoided.
• Cyclophosphamide: Concurrent use may increase the risk of myelosuppression (bone marrow toxicity).
• Cimetidine: Raises epirubicin exposure, potentially increasing toxicity; avoid concurrent use.
• Calcium-channel blockers (amlodipine, diltiazem): May increase the risk of heart failure when combined with epirubicin.
• Paclitaxel: Can increase epirubicin toxicity when used together.
• Live / modified-live vaccines: Live or live-attenuated vaccines may cause active infection in immunocompromised patients.
• Other antineoplastics / cyclosporine / ketoconazole / spinosad: Additional reported or theoretical anthracycline-class interactions include cyclosporine, glucosamine, other immunosuppressants (leflunomide, tacrolimus), ketoconazole, phenobarbital, spinosad, streptozocin, verapamil, warfarin and zidovudine; where the source names doxorubicin only, relevance to epirubicin is extrapolated.

Side Effects & Overdose

Side Effects

Adverse effects of epirubicin are primarily related to its cytotoxic activity and are often dose-dependent. Many effects involve the cardiovascular system, bone marrow, and gastrointestinal tract.

• Cardiotoxicity: Cumulative dose-dependent effect that may lead to cardiomyopathy and congestive heart failure, especially at higher total doses.
• Arrhythmias and tachycardia: Tachycardia and arrhythmias may occur during administration.
• Myelosuppression: Includes severe leukopenia and thrombocytopenia; requires routine CBC monitoring.
• Gastrointestinal toxicity: Anorexia, vomiting, pancreatitis, and hemorrhagic gastroenteritis may occur.
• Nephrotoxicity: May occur in some patients; in cats epirubicin is considered a potential nephrotoxin, so monitor renal function before and during treatment.
• Hypersensitivity reactions: Acute anaphylactic reactions may occur; treat promptly with adrenaline, corticosteroids and fluids.
• Hypersensitivity signs: Immediate histamine-mediated hypersensitivity may cause urticaria, facial swelling, vomiting, arrhythmias or hypotension; this reaction has also been reported in one cat.
• Alopecia and stomatitis: Hair-coat changes and oral ulceration (stomatitis) can occur; breeds with continuously growing coats (poodles, terriers, Afghan hounds, Old English sheepdogs) are more likely to experience significant alopecia.
• Timing of effects: Based on doxorubicin experience and considered probable for epirubicin, nausea and vomiting may occur within 72 hours, diarrhoea at 4–5 days, and the myelosuppression nadir at approximately 7–10 days after treatment.
• Discoloured urine: Urine may appear orange to red for 1–2 days after dosing — uncommon in animals and harmless.

Overdose

Overdose may exacerbate epirubicin’s adverse effects, particularly cardiotoxicity, myelosuppression and gastrointestinal toxicity.

• Severe cardiotoxicity, Profound myelosuppression and sever gastrointestinal toxicity: May be exacerbated on overdose.
• Management: Provide supportive and symptomatic treatment with monitoring guided by the patient’s clinical abnormalities.
• Toxicity threshold: A canine lethal dose is not publicly available; a 6-week repeated-IV-dose study identified 0.4 mg/kg/day as the Lowest Observed Adverse Effect Level, with the kidney as the target organ.
• Dexrazoxane: May be useful to help prevent cardiac toxicity after an overdose.
• Poison-control consultation: For a suspected overdose, consult a 24-hour poison-control centre with veterinary-specific expertise.

Key Notes

Practical clinical points that help optimize the safe and effective use of epirubicin in dogs and cats in oncology practice:

• Alternative to doxorubicin: May be considered as an alternative to doxorubicin when a similar antitumour effect is wanted with potentially lower cardiotoxic risk.
• Body surface area dosing: Standard canine dosing uses body surface area (mg/m²).
• Small patient adjustment: Dogs weighing under 10 kg may instead be dosed at 1 mg/kg.
• Combination protocols: May be used alongside other chemotherapeutic agents as part of multimodal cancer treatment.
• Cumulative dose awareness: Track the cumulative lifetime dose because cardiotoxicity is dose-dependent; the maximum total canine dose should not exceed 240 mg/m².
• Pre-treatment medication: Premedication with IV chlorphenamine or dexamethasone is recommended to reduce acute hypersensitivity reactions.
• Strict clinical setting use: Epirubicin should be prepared and administered only by personnel trained in cytotoxic-drug handling and chemotherapy administration.
• Handling protocols: Follow chemotherapy safety guidelines strictly to minimize occupational exposure.
• Extravasation treatment: Prevention is the priority; human-derived recommendations cited for veterinary extravasation include DMSO 99% applied over twice the affected area every 6 hours for 14 days without a dressing, dexrazoxane, and ice compresses (which may be useful) for 15 minutes every 6 hours for 3 days.
• Reconstitution & storage: Reconstitute the 50 mg vial with 25 mL sterile water to 2 mg/mL; the reconstituted solution should be clear and red — discard it if precipitation or significant discoloration is present. Do not mix with heparin or fluorouracil, and avoid prolonged contact with alkaline solutions (hydrolysis); reported compatible fluids include 5% dextrose, lactated Ringer’s and 0.9% sodium chloride.
• Storage: The stability of reconstituted solutions depends on preparation and storage conditions. Store refrigerated at 2–8°C and use according to validated institutional or manufacturer recommendations. Under appropriate storage conditions, stability may range from 24 hours to several weeks.
• Product storage: Store the lyophilised powder at 25°C (excursions 15–30°C); refrigerate the commercial solution at 2–8°C, do not freeze, and protect it from light.
• Client counselling: Warn clients that severe and potentially fatal toxicity can occur; tell them to contact the veterinarian immediately for profound depression, abnormal bleeding, bloody diarrhoea or bruising, and to avoid skin contact with the treated animal’s urine or faeces.
• Availability & evidence: Veterinary pharmacokinetic and pharmacodynamic data are lacking, and there is no veterinary-labelled epirubicin product — all use is with human-labelled product.